Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - temozolomide, quantity: 100 mg - capsule, hard - excipient ingredients: stearic acid; tartaric acid; colloidal anhydrous silica; purified water; microcrystalline cellulose; gelatin; sodium starch glycollate; iron oxide red; titanium dioxide; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; ethanol absolute; iron oxide black; ethanol; shellac; sulfuric acid - temozolomide is indicated for the treatment of:,- patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment. - recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as a first-line treatment for patients with advanced metastatic malignant melanoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - temozolomide, quantity: 250 mg - capsule, hard - excipient ingredients: iron oxide yellow; purified water; microcrystalline cellulose; colloidal anhydrous silica; sodium starch glycollate; gelatin; stearic acid; tartaric acid; titanium dioxide; iron oxide red; iron oxide black; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; ethanol absolute; ethanol; shellac; sulfuric acid - temozolomide is indicated for the treatment of:,- patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment. - recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as a first-line treatment for patients with advanced metastatic malignant melanoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - temozolomide, quantity: 140 mg - capsule, hard - excipient ingredients: tartaric acid; colloidal anhydrous silica; sodium starch glycollate; stearic acid; indigo carmine; microcrystalline cellulose; gelatin; purified water; titanium dioxide; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; ethanol absolute; iron oxide black; ethanol; shellac; sulfuric acid - temozolomide is indicated for the treatment of:,- patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment. - recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as a first-line treatment for patients with advanced metastatic malignant melanoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - temozolomide, quantity: 20 mg - capsule, hard - excipient ingredients: stearic acid; microcrystalline cellulose; colloidal anhydrous silica; sodium starch glycollate; tartaric acid; lactose; purified water; gelatin; titanium dioxide; iron oxide yellow; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; ethanol absolute; iron oxide black; ethanol; shellac; sulfuric acid - temozolomide is indicated for the treatment of:,- patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment. - recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as a first-line treatment for patients with advanced metastatic malignant melanoma.

European Union - English - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - temozolomide - glioma; glioblastoma - antineoplastic agents - temodal hard capsules is indicated for the treatment of:adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and subsequently as monotherapy treatment;children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.

European Union - English - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - temozolomide - glioma; glioblastoma - antineoplastic agents - temozolomide sun is indicated for the treatment of:adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy (rt) and subsequently as monotherapy treatment;children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - temozolomide, quantity: 140 mg - capsule, hard - excipient ingredients: indigo carmine; colloidal anhydrous silica; tartaric acid; gelatin; lactose; sodium starch glycollate; stearic acid; titanium dioxide; purified water; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.,treatment of recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as a first-line treatment for patients with advanced metastatic malignant melanoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - temozolomide, quantity: 250 mg - capsule, hard - excipient ingredients: purified water; tartaric acid; stearic acid; lactose; sodium starch glycollate; gelatin; colloidal anhydrous silica; titanium dioxide; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.,treatment of recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as a first-line treatment for patients with advanced metastatic malignant melanoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - temozolomide, quantity: 180 mg - capsule, hard - excipient ingredients: tartaric acid; stearic acid; lactose; iron oxide yellow; purified water; sodium starch glycollate; gelatin; titanium dioxide; iron oxide red; colloidal anhydrous silica; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.,treatment of recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as a first-line treatment for patients with advanced metastatic malignant melanoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - temozolomide, quantity: 100 mg - capsule, hard - excipient ingredients: gelatin; titanium dioxide; purified water; colloidal anhydrous silica; tartaric acid; sodium starch glycollate; stearic acid; iron oxide red; lactose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.,treatment of recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as a first-line treatment for patients with advanced metastatic malignant melanoma.